NRG肿瘤学RTOG 0415长期分析:比较两种分割方案治疗低危前列腺癌的随机III期非劣效性研究
NRG肿瘤学RTOG 0415是一项随机III期非劣效性试验,比较常规分割放疗(73.8 Gy/41次)与大分割放疗(70 Gy/28次)在低危前列腺癌患者中的疗效。中位随访12.8年更新结果显示,大分割组12年无病生存率非劣效于常规分割组,且生化失败率更低,两组晚期≥3级胃肠道及泌尿生殖系统不良事件无显著差异。
要点
- 大分割放疗(70 Gy/28次)长期无病生存非劣效于常规分割(73.8 Gy/41次),DFS HR 0.85(95%CI 0.71-1.03),非劣效P<.001。
- 大分割组12年生化失败累积发生率9.9%低于常规分割组17.0%,HR 0.55(95%CI 0.39-0.78)。
- 两组晚期≥3级胃肠道及泌尿生殖系统不良事件无显著差异。
核心结论
- 大分割放疗(70 Gy/28次)的长期无病生存非劣效于常规分割放疗(73.8 Gy/41次)。
- 大分割组生化失败发生率低于常规分割组。
- 两组晚期≥3级胃肠道及泌尿生殖系统不良事件无显著差异。
研究设计与样本
- NRG肿瘤学RTOG 0415是一项随机III期非劣效性临床试验,比较常规分割放疗(73.8 Gy/41次)与大分割放疗(70 Gy/28次)在低危前列腺癌患者中的疗效。
- 研究纳入1092例符合方案的患者,2016年首次报告时中位随访5.8年,本次更新中位随访12.8年。
主要发现
- 12年无病生存率常规分割组为56.1%(95%CI 51.5-60.5),大分割组为61.8%(95%CI 57.2-66.0),DFS风险比(大分割/常规分割)为0.85(95%CI 0.71-1.03),确认非劣效(P<.001)。
- 12年生化失败累积发生率常规分割组为17.0%(95%CI 13.8-20.5),大分割组为9.9%(95%CI 7.5-12.6),生化复发风险比(大分割/常规分割)为0.55(95%CI 0.39-0.78)。
- 晚期≥3级胃肠道不良事件发生率常规分割组为3.2%,大分割组为4.4%,大分割相对于常规分割的相对风险为1.39(95%CI 0.75-2.55)。
- 晚期≥3级泌尿生殖系统不良事件发生率常规分割组为3.4%,大分割组为4.2%,相对风险为1.26(95%CI 0.69-2.30)。
关键数值与推荐
- 非劣效性检验结果:DFS风险比(大分割/常规分割)0.85(95%CI 0.71-1.03),P<.001,确认非劣效。
- 生化失败风险比(大分割/常规分割)0.55(95%CI 0.39-0.78)。
- 晚期≥3级胃肠道不良事件相对风险(大分割 vs 常规分割)1.39(95%CI 0.75-2.55)。
- 晚期≥3级泌尿生殖系统不良事件相对风险(大分割 vs 常规分割)1.26(95%CI 0.69-2.30)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.NRG Oncology RTOG 0415 is a randomized phase III noninferiority (NI) clinical trial comparing conventional fractionation (73.8 Gy in 41 fractions) radiotherapy (C-RT) with hypofractionation (H-RT; 70 Gy in 28) in patients with low-risk prostate cancer. The study included 1,092 protocol-eligible patients initially reported in 2016 with a median follow-up of 5.8 years. Updated results with median follow-up of 12.8 years are now presented. The estimated 12-year disease-free survival (DFS) is 56.1% (95% CI, 51.5 to 60.5) for C-RT and 61.8% (95% CI, 57.2 to 66.0) for H-RT. The DFS hazard ratio (H-RT/C-RT) is 0.85 (95% CI, 0.71 to 1.03), confirming NI (P < .001). Twelve-year cumulative incidence of biochemical failure (BF) was 17.0% (95% CI, 13.8 to 20.5) for C-RT and 9.9% (95% CI, 7.5 to 12.6) for H-RT. The HR (H-RT/C-RT) comparing biochemical recurrence between the two arms was 0.55 (95% CI, 0.39 to 0.78). Late grade ≥3 GI adverse event (AE) incidence is 3.2% (C-RT) versus 4.4% (H-RT), with relative risk (RR) for H-RT versus C-RT 1.39 (95% CI, 0.75 to 2.55). Late grade ≥3 genitourinary (GU) AE incidence is 3.4% (C-RT) versus 4.2% (H-RT), RR 1.26 (95% CI, 0.69 to 2.30). Long-term DFS is noninferior with H-RT compared with C-RT. BF is less with H-RT. No significant differences in late grade ≥3 GI/GU AEs were observed between assignments (ClinicalTrials.gov identifier: NCT00331773).
引用
- Lee WR, Dignam JJ, Amin MB, et al. Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2024. PMID: 38759121. doi:10.1200/JCO.23.02445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。